top of page
jimeng-2025-06-26-4914-展示人体微环境内活跃的干细胞细胞群体,细胞呈现橘红色_edited.jpg

Immune Cell Manufacturing Platform

Comprehensive Cell Therapy Capabilities

Supports CAR-T, DC, NK, CAR-NK, and TIL therapies with tailored processes for each cell type.

Advanced Gene Delivery Technologies

Equipped for both viral and non-viral modification methods.

International-Standard GMP & Quality Control

End-to-end QC system covering raw materials, manufacturing, and final release to ensure safety and efficacy.

High Manufacturing Success Rate

Achives >95% success rate with high-positive-rate, low-impurity cell products.

Full Traceability & Process Automation

Closed-loop tracking from sample collection to clinical delivery, with key steps automated for precision and efficiency.

Modular & Scalable Design

Flexible configuration to meet research and clinical project needs, ensuring rapid adaptation to new therapies.

jimeng-2025-09-04-5084-生成一张细胞的图片(细胞上有car-t字样),色调干净明亮.png

CAR-T Core Manufacturing & Quality Control

At the heart of the platform is our CAR-T cell manufacturing system, which delivers high-purity, high-activity T cells through optimized isolation, viral vector transduction, and expansion processes. Stringent quality control covers every stage — from raw materials to final product release — including phenotype analysis, functional assays, sterility, and endotoxin testing, all in line with international standards and regulatory requirements.

Screenshot 2025-09-03 at 3.30.26 PM.png
jimeng-2025-07-03-4925-高质量显微镜照片: 几种不同类型、状态良好的细胞(如干细胞、免疫细胞)的清晰显微....png

Multi-Type Cell Therapy Capabilities

The platform supports diverse immune cell products, including CAR-T, DC, NK, CAR-NK, and TIL therapies. Each cell type is produced with tailored processes to maximize biological function and therapeutic potential. We employ both vital (lentiviral, retroviral) and non-viral (electroporation, transposon) gene delivery technologies, enabling flexible, safe, and efficient genetic modification based on project needs.

Platform Advantages

Our platform delivers >95% manufacturing success rates, high-positive-rate cell products, and low impurity levels to ensure safety and efficacy. Full traceability is implemented across collection, manufacturing, and delivery, with key processes automated to enhance precision, consistency, and efficiency. Modular design allows rapid customization for both research and clinical projects, ensuring adaptability to evolving therapeutic demands.

jimeng-2025-03-26-8165-生成一张图片,主体是CAR-T细胞,旁边有基因片段作为点缀。画面主体呈现代表生物..._edited.jpg
bottom of page